Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.

@article{Liu2014AromataseIB,
  title={Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.},
  author={Mohan Liu and Paul E Goss and James N. Ingle and Michiaki Kubo and Yoichi Furukawa and Anthony J Batzler and Gregory D. Jenkins and Erin E. Carlson and Yusuke Nakamura and Daniel J. Schaid and Jon William Chapman and Lois E. Shepherd and Matthew J. Ellis and Sundeep Khosla and Liewei Wang and Richard M. Weinshilboum},
  journal={Molecular endocrinology},
  year={2014},
  volume={28 10},
  pages={
          1740-51
        }
}
Bone fractures are a major consequence of osteoporosis. There is a direct relationship between serum estrogen concentrations and osteoporosis risk. Aromatase inhibitors (AIs) greatly decrease serum estrogen levels in postmenopausal women, and increased incidence of fractures is a side effect of AI therapy. We performed a discovery case-cohort genome-wide association study (GWAS) using samples from 1071 patients, 231 cases and 840 controls, enrolled in the MA.27 breast cancer AI trial to… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Similar Papers

Loading similar papers…